Reprogramming T-cell metabolism to enhance adoptive cell therapies
International Immunology · 27.04.2024 · 36 (6) · 261-278
DOI: 10.1093/intimm/dxae007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunology, online erschienen am 14.02.2024. Verfasst von Meghan Kates und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Haematology, Princess Margaret Cancer Center, University Health Network, 610 University Ave., Toronto, ON M5G 2M9,…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH.
Abstract (Originalsprache)
Adoptive cell therapy (ACT) is an immunotherapeutic approach that involves isolating T cells from a patient, culturing them ex vivo, then reinfusing the cells back into the patient. Although this strategy has shown remarkable efficacy in hematological malignancies, the solid-tumour microenvironment (TME) has presented serious challenges for therapy efficacy. Particularly, the TME has immunosuppressive signalling and presents a metabolically challenging environment that leads to T-cell suppression. T-cell metabolism is an expanding field of research with a focus on understanding its inherent link to T-cell function. Here, we review the current model of T-cell metabolism from naïve cells through effector and memory life stages, as well as updates to the model from recent literature. These models of metabolism have provided us with the tools and understanding to explore T-cell metabolic and mitochondrial insufficiency in the TME. We discuss manipulations that can be made to these mitochondrial and metabolic pathways to enhance the persistence of infused T cells, overcome the metabolically challenging TME and improve the efficacy of therapy in ACT models. Further understanding and investigation of the impact of metabolic pathways on T-cell performance could contribute to improving therapy efficacy for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology and Haematology, Princess Margaret Cancer Center, University Health Network, 610 University Ave., Toronto, ON M5G 2M9, Canada.
- Department of Immunology, University of Toronto, 1 King's College Circle, Toronto ON M5S 1A8, Canada.
ORCID-Profile: Meghan Kates
Förderung
- NIH
Zitieren
APA
Kates, M., & Saibil, S. D. (2024). Reprogramming T-cell metabolism to enhance adoptive cell therapies. International Immunology, 36(6), 261-278. https://doi.org/10.1093/intimm/dxae007
Vancouver
Kates M, Saibil SD. Reprogramming T-cell metabolism to enhance adoptive cell therapies. International Immunology. 2024;36(6):261-278. doi:10.1093/intimm/dxae007
BibTeX
@article{Kates2024,
author = {Kates, Meghan and Saibil, Samuel D},
title = {Reprogramming T-cell metabolism to enhance adoptive cell therapies},
journal = {International Immunology},
year = {2024},
volume = {36},
number = {6},
pages = {261--278},
doi = {10.1093/intimm/dxae007}
}
EUVIMED